What’s the current market cap for Viatris stock?

Viatris (VTRS) has a market cap of $19bn as of June 12, 2026.

What is the P/E ratio for Viatris stock?

The price to earnings (P/E) ratio for Viatris (VTRS) stock is 0 as of June 12, 2026.

Does Viatris stock pay dividends?

Yes, the Viatris (VTRS) stock pays dividends to shareholders. As of June 12, 2026, the dividend rate is $0.48 and the yield is 2.94%. Viatris has a payout ratio of 0% on a trailing twelve-month basis.

When is the next Viatris dividend payment date?

The next Viatris (VTRS) dividend payment is scheduled for June 17, 2026.

What is the beta indicator for Viatris?

Viatris (VTRS) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Viatris stock | $VTRS Share Price

13:30

15:10

16:45

18:25

20:00

About Viatris

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Ticker

$VTRS

Sector

Health

Primary listing

NASDAQ

Employees

30,000

Headquarters

Canonsburg, United States

Website

www.viatris.com

Viatris Metrics

BasicAdvanced

$19bn

-$0.26

0.90

$0.48

2.94%

What the Analysts think about Viatris

Analyst ratings (Buy, Hold, Sell) for Viatris stock.

Bulls say / Bears say

Viatris topped analysts’ estimates for first-quarter revenue and profit, posting adjusted EPS of $0.59 versus the LSEG consensus of $0.50, buoyed by 22% reported revenue growth in Greater China (Reuters)

Brands net sales grew 10% reported and 4% operational to $2.33 billion in Q1, highlighting the resilience and high-margin potential of its legacy product portfolio (PR Newswire)

Since December 2025, Viatris secured four regulatory milestones—including FDA approval of generic octreotide LAR, FDA acceptance of its low-dose estrogen patch NDA (PDUFA July 30, 2026), IND clearance for MR-146 gene therapy, and PMDA acceptance for pitolisant in OSAS—diversifying its pipeline across generics and specialty therapies (PR Newswire)

U.S. GAAP gross margin declined to 32.9% in Q1 2026 from 35.7% a year earlier, indicating margin compression amid mix shift and pricing headwinds (PR Newswire)

U.S. GAAP net cash provided by operating activities dropped 27% year-on-year to $388 million and free cash flow, excluding transaction and restructuring costs, fell 14% to $459 million, signaling weakening cash generation (PR Newswire)

Supply constraints in its antiretroviral (ARV) business within Emerging Markets partially offset generics growth, resulting in generics operational net sales growth of only 1% in Q1 (PR Newswire)

Data summarised monthly by Lightyear AI. Last updated on 23 May 2026.

Viatris Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Viatris Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VTRS

Capital at risk

Market closed

Upcoming events

Bulls say / Bears say

Brands net sales grew 10% reported and 4% operational to $2.33 billion in Q1, highlighting the resilience and high-margin potential of its legacy product portfolio (PR Newswire)

U.S. GAAP gross margin declined to 32.9% in Q1 2026 from 35.7% a year earlier, indicating margin compression amid mix shift and pricing headwinds (PR Newswire)

Supply constraints in its antiretroviral (ARV) business within Emerging Markets partially offset generics growth, resulting in generics operational net sales growth of only 1% in Q1 (PR Newswire)

Data summarised monthly by Lightyear AI. Last updated on 23 May 2026.